Nature communications

Anti-inflammatory lipid nanoparticles allow targeted mRNA treatment for inflammatory bowel disease

Updated

Abstract

MP2 lipid nanoparticles (LNPs) demonstrated a 15-fold higher delivery efficiency in vivo compared to FDA-approved SM102 LNPs.

  • MP2 LNPs, when loaded with interleukin-35 (IL-35) mRNA, improved clinical outcomes in mouse models of acute and chronic inflammatory bowel disease (IBD).
  • Treatment with MP2-IL-35 LNPs resulted in preserved colon length and decreased levels of pro-inflammatory cytokines.
  • In human colonic biopsies, MP2 LNPs were effective in delivering mRNA to immune, epithelial, and endothelial cells.
  • MP2-IL-35 LNPs significantly altered the subsets of effector and regulatory T cells in biopsies from patients with IBD.

Simplified

Full Text

Full text is available at the source.

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free